Mar 09,2022

DDM Health selected in Amazon Web Services (AWS) UK Healthcare Accelerator

DDM is excited to announce that it has been selected as one of the 12 participants selected for the first ever AWS Healthcare Accelerator in the UK. As a a multi-award-winning provider of digital therapeutics, DDM was selected from 117 applications across 13 countries, including the UK, by a panel from Amazon Web Services (AWS) and PUBLIC.

View Analyst & Ambassador Comments
Go to original news
Jul 26,2021

FARMALISTO AND SOCIALDIABETES SIGN A STRATEGIC ALLIANCE TO LAUNCH A COMPREHENSIVE DIABETES MANAGEMENT PROGRAM IN LATIN AMERICA

SocialDiabetes, the leading digital solution for diabetes management, and Farmalisto, the leading MedTech and pharmacy platform in Latin America, have announced a strategic alliance to launch a telemedicine platform aimed at transforming diabetes management and radically improving the lives of patients. In collaboration with SocialDiabetes, Farmalisto is poised to launch an innovative patient-centered integrated care program that, thanks to mobile technology, telemedicine, and universal connectivity of medical devices (IoT), allows for remote monitoring of patients, data management in real-time, and the analysis of patient behavioral patterns, providing personalized and effective healthcare. This innovative program will be launched in Colombia, Mexico, Chile, and Peru during the second half of 2021, and it is expected to expand throughout Latin America in the following year.

COLLABORATION PARTNERSHIP

#r&d

#telehealth

#rpm

View Analyst & Ambassador Comments
Go to original news
Jul 16,2021

Innovation Zed and SocialDiabetes Announce Global Partnership to Improve Health Outcomes for People With Diabetes

Innovation Zed Ltd., the developer of novel Insulin Pen “InsulCheck CONNECT” add-on device, and SocialDiabetes, a leading diabetes management company, today announced the signing of a global partnership and data integration agreement. As a result of this new partnership, the companies will pursue joint efforts to promote and sell their products as a single integrated system to improve health outcomes for people with diabetes.

COLLABORATION PARTNERSHIP

#connected device

#insulin pen

#mobile app

View Analyst & Ambassador Comments
Go to original news
Apr 01,2020

Axenya and SocialDiabetes sign a collaboration agreement to test and launch Digital Health Software in Latin-America

SocialDiabetes ?announces that it has signed a collaboration agreement with AXENYA , a Latin-America digital health? ?platform company.? Axenya is a Latin American digital health ecosystem aggregator with a mission to empower Latin-America’s? ?doctors and patients to plug into the future of medicine.

COLLABORATION PARTNERSHIP

#institution

#mobile app

View Analyst & Ambassador Comments
Go to original news
May 10,2023

Second Nature launches new AI health coaching tool: CoachGPT

Second Nature announce an addition to its lifestyle change programme – CoachGPT. CoachGPT is an AI health coach designed to provide people with personalised guidance, motivation, and support as they work towards achieving their lifestyle goals. Currently available for free to everyone, the AI-coach is in the beta version. The company is expecting to evaluate the feedback from the users.

PRODUCT

#coaching

View Analyst & Ambassador Comments
Go to original news

Top5 Digital Diabetes Companies with Most Partnerships in 2022

Summary

This expert-led presentation on the Top5 Digital Diabetes companies with highest number of partnerships in 2022 provides insights about the status on the collaborations in the digital diabetes market, the list of top5 digital diabetes companies with the most partnerships and the top5 companies’ partnership snapshots in 2022 including their partnership strategies.

Author: Melis Ince, Senior Market Analyst and Consultant at Research2Guidance

Feb 09,2022

Abbott Diabetes Care and Sugar.fit Partner for Diabetes Care in India

Abbott, the global healthcare leader, announced new collaborations with key health-tech partners Sugar.fit, and 7 other companies in India to usher a new era of holistic diabetes management care. Madan Somasundaram, Co-founder and CEO, Sugar.fit said, "At Sugar.fit, our mission is to empower people with chronic conditions to live better and healthier lives and reverse chronic metabolic disorders. Technology is combined with science and human coaching to help millions of Indians manage and reverse diabetes through a highly consumer-centric data-driven digital health experience."

COLLABORATION PARTNERSHIP

#connected device

#cgm

View Analyst & Ambassador Comments
Go to original news
Feb 09,2022

Abbott Diabetes Care India Announces Partnerships with HealthifyMe, GOQii and 7 Others

Abbott, the global healthcare leader, announced new collaborations with key health-tech partners Healthifyme, GOQii and 7 others (BeatO, Sugar.fit, PharmEasy, , 1MG, Zyla Health, and Fitterfly) to usher a new era of holistic diabetes management care. 

COLLABORATION PARTNERSHIP

#connected device

#cgm

View Analyst & Ambassador Comments
Go to original news
Feb 08,2022

Abbott Announces Partnerships with 1MG, PharmEeasy and 7 Other in India

Abbott, a global healthcare leader, has partnered with key health-tech firms including BeatO, Sugar.fit, PharmEasy, GOQii, 1MG, Zyla Health, Healthifyme and Fitterfly to usher in a new era of holistic diabetes management care. Through these collaborations, Abbott aims to offer glucose monitoring solutions to 8 million people living with diabetes, of which approximately 6.5 million users can access through PharmEasy and 1MG. The company is focused on maintaining effective glucose level along with remote consultations, diabetes-specific coaching, and dietary plans.
 

COLLABORATION PARTNERSHIP

#institution

#cgm

View Analyst & Ambassador Comments
Go to original news
Nov 21,2019

Astellas and Welldoc Enter into Strategic Alliance for Digital Therapeutics

Astellas Pharma Inc. and Welldoc, Inc. today announced that the companies have entered into a collaboration and license agreement directed toward the development and commercialization of digital health solutions. Under the agreement, Astellas and Welldoc will jointly develop and commercialize BlueStar in Japan and certain other Asian markets for patients with diabetes, collaborate to broaden the adoption of BlueStar in the U.S. market, and jointly develop and commercialize digital therapeutics in other therapeutic areas globally. Under the terms of the  agreement, Astellas will make an upfront payment of $15 million to Welldoc. In addition, the agreement includes development and commercialization milestones as well as royalties on any future product sales.

COLLABORATION PARTNERSHIP

#r&d

#dtx

View Analyst & Ambassador Comments
Go to original news
Subscribe to DIABETES